Clinical Trial Update: An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder [Phase 4]

View source ↗

Summary

A Phase 4 open-label trial evaluating memantine for cognitive impairment in patients with post-traumatic stress disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• Memantine (memantine)

Snippet

Sponsor: Sriram Ramaswamy | Conditions: PTSD | Phase 4 | Status: COMPLETED